Study to Evaluate Nipocalimab in Participants with Active Idiopathic Inflammatory Myopathies
Recruiting
18 years - 90 years
All
Phase
2
3 participants needed
1 Location
Brief description of study
The purpose of this study is to see if the investigational drug nipocalimab is safe and useful for treating patients with active Idiopathic Inflammatory Myopathies (IIM).
Another purpose is to find out if nipocalimab can cause side effects, which are unexpected or unwanted reactions from taking a drug. An
investigational drug is one that is not approved by the United States Food and
Drug Administration (FDA) for treating IIM.
Detailed description of study
We will use
your personal health information, information from the tests and procedures
done for the study, and information about how the study drug affects you to
help determine if the study drug is safe and effective in treating IIM.
You will be
randomly assigned to receive either nipocalimab or placebo. A placebo is an inactive substance or other intervention that looks the
same as, and is given the same way as, an active drug or treatment
being tested.
This is a double-blind study, which
means that you and the study team will not know which group you are in.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Idiopathic Inflammatory Myopathies,IIM,rheumatology
-
Age: 18 years - 90 years
-
Gender: All
Updated on
04 Aug 2024.
Study ID: 852070
Find a site
,
Your Information has been sent successfully.
Send a message
Enter your contact details to connect with study team
Primary Contact
